Evidence map›Paper›PMID 37046731›Full record

ArticleCancers2023

High-Multiplex Aptamer-Based Serum Proteomics to Identify Candidate Serum Biomarkers of Oral Squamous Cell Carcinoma.

Sebastian Blatt, Peer W Kämmerer, Maximilian Krüger, Rambabu Surabattula, Daniel G E Thiem, Simon T Dillon, Bilal Al-Nawas, Towia A Libermann, Detlef Schuppan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Sebastian BlattDepartment of Oral and Maxillofacial Surgery, University Medical Center, 55131 Mainz, Germany.
Peer W KämmererDepartment of Oral and Maxillofacial Surgery, University Medical Center, 55131 Mainz, Germany.ORCID 0000-0002-1671-3764
Maximilian KrügerDepartment of Oral and Maxillofacial Surgery, University Medical Center, 55131 Mainz, Germany.
Rambabu SurabattulaInstitute of Translational Immunology and Research Center for Immune Therapy (FZI), University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.
Daniel G E ThiemDepartment of Oral and Maxillofacial Surgery, University Medical Center, 55131 Mainz, Germany.ORCID 0000-0002-4081-1487
Simon T DillonBeth Israel Deaconess Medical Center Genomics, Proteomics, Bioinformatics and Systems Biology Center, Division of Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Bilal Al-NawasDepartment of Oral and Maxillofacial Surgery, University Medical Center, 55131 Mainz, Germany.ORCID 0000-0002-8665-5803
Towia A LibermannBeth Israel Deaconess Medical Center Genomics, Proteomics, Bioinformatics and Systems Biology Center, Division of Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-4006-8179
Detlef SchuppanInstitute of Translational Immunology and Research Center for Immune Therapy (FZI), University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.
Johannes Gutenberg University Mainz · DEBeth Israel Deaconess Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Improved serological biomarkers are needed for the early detection, risk stratification and treatment surveillance of patients with oral squamous cell carcinoma (OSCC). We performed an exploratory study using advanced, highly specific, DNA-aptamer-based serum proteomics (SOMAscan, 1305-plex) to identify distinct proteomic changes in patients with OSCC pre- vs. post-resection and compared to healthy controls. A total of 63 significantly differentially expressed serum proteins (each

Indexed as

biomarkerliquid biopsyoral cancerprognosisproteomicsserumSOMAscantherapy

Identifiers

PMID37046731
PMCPMC10093013
OpenAlexW4362519949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.